SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to a recent partnership with Semtech for AI and cloud network optical engines, sparking optimism about potential collaborations with major Semtech customers like Apple, Amazon, and Intel. The community is discussing the high trading volume and potential for a significant breakout, with some anticipating a short squeeze and long-term growth in the AI connectivity sector. Investors are also excited by the large 2027 call option volume, possibly indicating a large long term position is being built.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as investors discuss its AI cloud services and potential for significant growth in the AI data center market. Community members are highlighting the company's multi-year contracts, revenue projections, and strategic shift from Bitcoin mining to AI infrastructure. Some analysts have given IREN a high price target, contributing to the positive sentiment.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

Galecto (GLTO) is experiencing significant volatility, driven by a high short interest and low float, leading to a battle between bulls anticipating a short squeeze and bears predicting a crash. The community is actively debating potential price targets and whether it can emulate similar runs seen in other stocks. This action is occurring without any specific news catalyst, contributing to the speculative nature of the trading activity.

NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

NuCana plc - ADR

NuCana plc

NuCana ($NCNA) is trending due to renewed interest in its low float and upcoming data presentation at the ESMO Congress in October, sparking speculation of a potential squeeze. The community is drawing comparisons to other low-float runners and highlighting the company's strong cash runway into 2029. Some investors are also pointing to a recently published research article as a potential catalyst.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the community rallies around its vision of natural wellness and plant-based healing, contrasting with traditional pharmaceuticals. Community members are sharing links to the Weedcoin website and highlighting its connection to cannabis culture. The coin aims to promote accessibility and normalize natural medicine.

Trilogy Metals, Inc. engages in the development and exploration of mineral properties. The firm holds interests in the Upper Kobuk mineral projects that include the Arctic, a copper-zinc-lead-gold-silver and Bornite, a carbonate-hosted copper projects, which is located in the Ambler mining district in Northwest Alaska. The company was founded on April 27, 2011 and is headquartered in Vancouver, Canada.

Trilogy Metals Inc

Trilogy Metals is trending following news of a U.S. government investment, acquiring a 10% stake to support critical mineral exploration in Alaska. Community discussions revolve around a potential short squeeze and whether the stock can reach double digits, though some caution against chasing the rally and point to a possible offering. The surge reflects a broader interest in securing domestic mineral resources.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as chatter increases around its merger with quantum computing company Infleqtion. The community highlights Infleqtion's existing contracts, partnership with NVIDIA, and potential for growth compared to sector peers like $IONQ and $RGTI. Some investors believe $CCCX is currently undervalued and presents a compelling entry point into the quantum computing space.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending amidst community discussions about a potential new, more affordable Model Y, with debates focusing on its impact on existing Tesla owners and competition within the EV market; some are skeptical, while others anticipate a positive effect on sales volume and market share, especially as the new models offset the end of US tax incentives.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

$TMC is trending amid renewed interest in deep-sea mining, with investors closely watching for potential government partnerships and regulatory approvals, especially regarding the NOAA decision. The community is actively discussing the possibility of a short squeeze and the stock's breakout potential. Bullish sentiment is driven by the company's long-term prospects in the critical minerals market.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is surging amid speculation of a partnership with Tesla, fueled by a teaser video and social media buzz. The community is actively discussing potential price targets and short squeeze opportunities, while also weighing the risks of the rumors being unfounded. Broader interest in the eVTOL sector and Archer's existing partnerships are also contributing to the conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of -28.05% and -0.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of UroGen Pharma gained momentum after the U.S. FDA approved Zusduri, a therapy for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer, prompting a flurry of bullish analyst revisions and heightened interest from retail investors.UroGen Pharma shares jumped 8.6% to $12.03 on Friday, hitting a three-month high, and edged up further to $12.06 in after-hours trading.Goldman SachsGoldman Sachs raised its price target to $16 from $3, noting the stock’s 22% post-approval rally surprised most investors, given the negative ODAC vote and briefing document that had flagged an unfavorable benefit-risk profile.&nbsp;In a note, analyst Paul Choi reminded investors that FDA approvals following negative oncology advisory panels are “exceedingly rare.”&nbsp;The firm remains ‘Neutral’ on the stock despite the unexpected regulatory success.OppenheimerOppenheimer raised its target to $31 from $10, reiterating an ‘Outperform’ rating and emphasizing a key update from Friday’s conference call—a $21,500 per-dose list price for Zusduri.&nbsp;Analyst Leland Gershell expects clarity on UGN-103's path to approval will help preserve franchise exclusivity beyond 2031, adding that sales could reach $1 billion over time.&nbsp;He also said he would “take advantage of any near-term weakness to buy UroGen shares.”ScotiabankScotiabank lifted its target to $47 from $23, increasing its FDA approval probability from 60% to 100%.&nbsp;The firm continues to rate the stock ‘Outperform,’ citing a $1 billion peak market opportunity for Zusduri and revising valuation models accordingly.<a href="https://stocktwits.com/news-articles/markets/equity/urogen-price-target-upgrade-after-fda-approval-for-cancer-medicine/chli4GKRRbJ">Guggenheim and D. Boral</a> also reaffirmed bullish views on UroGen Pharma, calling the FDA's early approval of Zusduri a 'surprise decision' that bypassed further trial requirements and validated regulatory flexibility in high-unmet-need cancer settings.The drug, a combination of mitomycin and sterile hydrogel, is administered once weekly for six weeks via catheter, offering a non-surgical alternative to transurethral resection of bladder tumors, the current standard of care.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.The stock has risen 12.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Illustration depicting tumour infiltrating lymphocyte (TIL) therapy for cancer treatment. During TIL therapy, T-cells (blue) that recognise tumour cells (red) are obtained from a patient. | Image source: Getty Images

UroGen Pharma Stock Scores Bullish Price Target Revisions Up To $47 Following FDA Nod For Zusduri

UroGen Pharma shares rallied to a three-month high after the FDA approved Zusduri, a non-surgical treatment for a type of bladder cancer.

Equity

Shares of UroGen Pharma (URGN) shot up 9% on Friday morning after Guggenheim hiked its price target on the stock on the heels of the U.S. Food and Drug Administration approving its Zusduri medication.The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.urogen.com/news-releases/news-release-details/us-fda-approves-urogens-zusduritm-mitomycin-intravesical">approved</a> Zusduri for adults with a type of cancer of the lining of the bladder called recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer (LG-IR-NMIBC) on Thursday. Zusduri consists of mitomycin and sterile hydrogel and is designed for potent tumor ablation.Patients can receive their Zusduri dose from a healthcare provider once a week for 6 weeks into the bladder through a urinary catheter, as opposed to the existing standard of care which is a surgical procedure called transurethral resection of bladder tumor.Guggenheim subsequently raised the firm's price target on UroGen Pharma to $30 from $15 while keeping a ‘Buy’ rating on the shares.The new price target implies a near 171% upside to the stock’s closing price of $11.08 on Thursday.The FDA approval for Zusduri, a day ahead of the deadline, is "a surprise decision" following the negative Oncologic Drug Advisory Committee (ODAC) vote during an FDA advisory committee meeting last month, the analyst told investors, as per TheFly.Last month, the ODAC committee narrowly voted against its benefit/risk profile, effectively ending hopes for approval as the FDA considers independent advice from the committee.The firm believes this outcome represents a best-case scenario for UroGen, given that the marketing approval indicates a broad indication of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, without the need to conduct another large randomized controlled trial and "only minor safety warnings."D. Boral Capital analyst Jason Kolbert, meanwhile, reiterated a ‘Buy’ rating and $25 price target on UroGen Pharma. The approval validates the FDA's willingness to exercise flexibility in high-unmet-need indications, despite divided advisory input, the analyst said.Zusduri is expected to be available in the U.S. on or around July 1, 2025, for the treatment of adults with recurrent LG-IR-NMIBC. LG-IR-NMIBC affects approximately 82,000 people in the U.S. each year, and of those, an estimated 59,000 are recurrent cases.On Stocktwits, retail sentiment around UroGen rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume increased from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1274/136;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_13_at_9_30_23_AM_png_01d194b268.webp" alt="URGN's Sentiment Meter and Message Volume as of 9:30 a.m. ET on Jun 13, 2025 | Source: Stocktwits" width="1274" height="136"><figcaption>URGN's Sentiment Meter and Message Volume as of 9:30 a.m. ET on Jun 13, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism that the stock would reach $20.<stembedurl>https://stocktwits.com/TarriffKing007/message/617822498</stembedurl><a href="https://stocktwits.com/symbol/URGN">URGN stock</a> is up approximately 13% this year but down by 31% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-inks-5.3-billion-deal-with-cspc-pharma-for-new-drug-candidates/chli5sARRbG">AstraZeneca Inks $5.3B Deal With CSPC Pharma For Developing New Oral Drug Candidate, But Retail’s In No Mood To Cheer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

UroGen Soars On Price Target Upgrade On Heels Of FDA Approval For Cancer Medicine: Retail Sees Stock Touching $20

The new price target of $30 implies a near 171% upside to the stock’s closing price of $11.08 on Thursday.

Shares of biotech company UroGen Pharma Ltd. (URGN) plummeted 48% on Wednesday noon after the company said that a committee of the U.S. Food and Drug Administration (FDA) voted in opposition to a favorable benefit-risk profile for its investigational drug UGN-102, an intravesical solution for the treatment of a recurrent form of bladder cancer.CEO Liz Barrett <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250521737507/en/UroGen-Announces-Outcome-of-Oncologic-Drugs-Advisory-Committee-for-UGN-102-for-the-Treatment-of-Recurrent-Low-Grade-Intermediate-Risk-Non-Muscle-Invasive-Bladder-Cancer-LG-IR-NMIBC">said</a> the company is "disappointed" by the outcome of the meeting of FDA’s Oncologic Drugs Advisory Committee (ODAC), but added that the company believes in the clinical data in support of the drug.Low-grade intermediate-risk nonmuscle-invasive bladder cancer has no FDA-approved therapies, the CEO said, while adding that it is looking forward to working with the FDA as they complete their review of its new drug application (NDA).The FDA considers independent advice from ODAC, which weighs down the possibility of approval. The FDA is expected to conclude its review of the application by June 13.UGN-102 for intravesical solution is an innovative drug formulation of mitomycin, an antibiotic used as a drug in cancer treatment. It stops or slows the growth of cancer cells and other rapidly growing cells by damaging their DNA.The company said the adverse impacts identified with the treatment in its late-stage trial, such as urine retention, are typically manageable in routine urologic practice. &nbsp;UroGen submitted its NDA to the FDA in August 2024. If approved in June, the company initially said it would make the product available in July.On Stocktwits, retail sentiment around UroGen remained unchanged within the ‘extremely bullish’ territory over the past 24 hours while message volume stayed put at ‘extremely high’ levels. &nbsp;<figure class="image"><img style="aspect-ratio:626/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_21_at_1_58_13_PM_png_0f90b9f92d.webp" alt="URGN's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 21, 2025 | Source: Stocktwits" width="626" height="65"><figcaption>URGN's Sentiment Meter and Message Volume as of 1:55 p.m. ET on May 21, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/URGN">URGN stock</a> is down by about 64% this year and nearly 71% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/shopify-bets-on-gen-ai-with-new-ai-tools-to-simplify-store-creation-but-stock-drops/ch0eOwYRbYo">Shopify Bets On Gen-AI With New AI Tools To Simplify Store Creation But Stock Drops</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

UroGen Stock Slumps After FDA Advisory Committee Flag Concerns On Its Investigational Drug: But Retail’s Unruffled

The Food and Drug Administration is expected to conclude its review of UroGen’s UGN-102 application by June 13.

UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will...

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced expansion of its...

UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from the...

UroGen Pharma to Present at Upcoming Investor Conferences

ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the 3-month...

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of...

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

UroGen Pharma Ltd

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

URGN UroGen Pharma Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest URGN News